10x Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by stock analysts at Barclays from $55.00 to $45.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 27.37% from the […] Read this story
